Diagnosis, management, and outcomes of parechovirus infections in infants: an overview.
Anjana SasidharanChristopher J HarrisonRangaraj SelvaranganPublished in: Journal of clinical microbiology (2024)
Parechovirus A (PeV-A) infections have been detected with increasing frequency in US infants under 6 months of age, leading to a Centers for Disease Control and Prevention (CDC) health advisory in July 2022. Clinicians are advised to consider PeV-A laboratory testing of blood and cerebrospinal fluid when infants present with unexplained fever, sepsis-like illness, or neurological issues. Clinical laboratories are encouraged to offer in-house molecular testing for PeV-A to avoid diagnostic delays, unnecessary use of antibiotics, and prolonged hospitalization of infants presenting with sepsis-like illness. While data are evolving on potential neurodevelopmental sequelae after PeV-A infant central nervous system infections, most infected infants return to baseline health for age. This review examines the PeV-A literature with a focus on PeV-A3, including aspects of epidemiology, clinical presentations/management, laboratory diagnostics, genotyping, and post-infectious sequelae related to PeV-A infections in infants.
Keyphrases
- cerebrospinal fluid
- healthcare
- public health
- acute kidney injury
- intensive care unit
- systematic review
- health information
- gene expression
- cell cycle
- septic shock
- palliative care
- risk assessment
- brain injury
- cell proliferation
- electronic health record
- skeletal muscle
- single molecule
- drug induced
- congenital heart disease
- cerebral ischemia